Sorry, you need to enable JavaScript to visit this website.

Mechanism of Action | RYBREVANT® (amivantamab-vmjw) HCP

The first and only approved EGFR-MET bispecific antibody with immune cell–directing activity1


RYBREVANT® targets multiple disease mechanisms in patients with EGFR exon 20 insertion mutations1,2:

RYBREVANT® blocks EGFR and MET activity


EGFR and MET activity

RYBREVANT® degrades EGFR and MET receptors



RYBREVANT® activates immune cell responses to kill tumor cells


immune cell responses

*Trogocytosis is a process in which one cell, in this case macrophages, physically extracts and ingests cellular material of another cell.2

Antibody-dependent cellular cytotoxicity (ADCC) involves the release of cytotoxic granules that cause tumor cell death.2,3

Mechanism of Action Video

EGFR exon 20 insertion mutations in mNSCLC mechanism of disease

Combining the ability of RYBREVANT® to engage immune cells with chemotherapy-mediated cell death could have complementary antitumor activity4,5



It's time for a new first-line treatment for patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.

Explore the clinical data

EGFR, epidermal growth factor receptor; MET, mesenchymal-epithelial transition; NSCLC, non-small cell lung cancer.


Register for Updates

Sign up to receive the latest news and information about RYBREVANT® by completing the registration form.


1. RYBREVANT® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.

2. Cho BC, Simi A, Sabari J, et al. Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications. Clin Lung Cancer. 2023;24(2):89-97.

3. Grugan KD, Dorn K, Jarantow SW, et al. Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing in lung cancer cells. MAbs. 2017; 9(1):114-126.

4. Zhou C, Tang K-J, Cho BC, et al; PAPILLON Investigators. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. N Engl J Med. 2023;389(22):2039-2051.

5. Nagasaka M, Goto K, Gomez J, et al. Amivantamab in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Poster presented at IASLC World Conference on Lung Cancer. 8-14, 2021.